← All trials
NCT06401330
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2024
- Primary completion
- Feb 13, 2031
- Completion date
- Feb 13, 2031
- First posted
- May 6, 2024
- Last posted
- Aug 12, 2024
- Enrollment
- 1656
- Arms / groups
- 46 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.